Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 153 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lopinavir/ritonavir Clear all

Conditions: HIV Infections
Interventions: Atazanavir, Lopinavir/Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more

Conditions: Diabetes, HIV Infections, Insulin Resistance
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 72 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 7
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 4 more

Conditions: Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 28 Days and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: HIV Infections
Interventions: Kaletra + Isentress, Pre-study antiretroviral regimen; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Acetylcholine, L-NMMA; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Days to 6 Months
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 14
States / cities: Oakland, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: lopinavir/ritonavir plus maraviroc; Drug
Lead sponsor: Rodwick, Barry M., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Safety Harbor, Florida

Conditions: HIV Infections
Interventions: lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 27
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 20 more

Conditions: HIV Infection
Interventions: emtricitabine/tenofovir, abacavir/lamivudine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: HIV Infections
Interventions: Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Torrance, California + 16 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Beverly Hills, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: HIV Infections
Interventions: lopinavir/ritonavir plus maraviroc; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: HIV Infections
Interventions: atazanavir/ritonavir, lopinavir/ritonavir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID, COVID-19, Corona Virus Infection, Coronavirus Infection, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, Coronavirus-19, SARS-CoV 2, SARS Pneumonia
Interventions: hydroxychloroquine, Azithromycin, Ritonavir, Lopinavir; Drug
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ventura, California

Conditions: HIV Infections
Interventions: Medroxyprogesterone acetate, Estradiol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV Infections
Interventions: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Kaletra; Drug
Lead sponsor: Therapeutic Concepts; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Phoenix, Arizona • Laguna Beach, California • Washington D.C., District of Columbia + 5 more

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions: Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy
Interventions: Raltegravir, lopinavir, ritonavir; Drug
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Human Immunodeficiency Virus
Interventions: emtricitabine/tenofovir disoproxil fumarate; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Kaletra-isentress Treatment Evaluation

The Effect of Lopinavir/Ritonavir on Endothelial Function

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Metabolic Effects of Switching Kaletra to Boosted Reyataz

A Study of Combination Therapies to Treat COVID-19 Infection

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

HIV Antiretroviral Drugs and Metabolism

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

CiPA Phase 1 ECG Biomarker Validation Study

Raltegravir Kaletra Pharmacokinetics

Post-Exposure Prophylaxis in Health Care Workers